Q-omics provides the consensus-scored KCNS2 profile across patient tissues and cancer cell-line models. KCNS2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCNS2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KCNS2 RNA expression shows 15,686 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where KCNS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNS2 survival associations across molecular data types. KCNS2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNS2 RNA expression–survival associations across cancer types. High KCNS2 expression shows unfavorable associations in KIRP, BLCA and CESC, but favorable associations in BRCA, LUAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCNS2 RNA expression.
This table summarizes KCNS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNS2 shows lower tumor expression in KIRC, COAD, UCEC, KICH, STAD and READ. The KIRC box plot shows higher KCNS2 RNA expression in normal versus tumor tissue (log2 FC = −0.326, t-test p < 0.001).
This table shows molecular features associated with KCNS2 in patient tissues and cancer cell lines. In patient samples, KCNS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
